Skip to main content

Advertisement

Log in

Validation of the German prostate-specific module

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Theoretically, all patients newly diagnosed with prostate cancer are faced with a choice of treatment options: radical prostatectomy or radio therapy. Although these different treatments may have no differences in terms of survival, they may have very different consequences on the subsequent quality of life (QoL). Prerequisite to analyze QoL is a reliable and valid instrument to assess these differences not only in terms of general QoL (EORTC QLQ-C30) but prostate specific symptoms with a prostate specific module as well. Therefore, the aim of this study was a psychometric evaluation (validation) of the prostate-specific module (PSM). Five historical cohort studies were put together for an empirical meta-analysis. The main objective was to analyze the module’s psychometric properties. The total sample consisted of 1,185 patients, of whom 950 completed the QoL questionnaires (EORTC QLQ-C30 and a prostate specific module developed by Kuechler et al.). First step of analysis was a principal component analysis that revealed the following scales: urinary problems, incontinence, erectile dysfunction, sexual problems, problems with partner, pain, heat, nutrition, and psychic strain. The module showed good reliability and concurrent validity and very good construct validity, since the module is able to discriminate between different treatment regimes, tumor stages and age. The German PSM is a reliable, valid and applicable tool for QoL in patients with prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parker ME (1997) PSA thresholds for prostate cancer detection. JAMA 278(9):699–700

    Article  PubMed  CAS  Google Scholar 

  2. Tannock I (1995) Will increases in chemotherapy dose intensity improve outcome of patients with common malignancies? Am J Med 99(6A):68S–69S

    Article  PubMed  CAS  Google Scholar 

  3. Biermann CW and Küchler T, „Lebensqualität in der urologischen Onkologie” in: Herbert Rübben (Hrg.): Uroonkologie; 3.ed., Springer 2001: 917–930

  4. Sprangers MAG, Cull A, Bjordal K, Groenvold M, Aaronson NK for the EORTC STUDY GROUP ON QUALITY OF LIFE (EORTC-QOL). The European organization for research and treatment of cancer approach to the quality of life (QOL) assessment: guidelines for developing questionnaire modules. Quality of Life Research 3:67–68, 1994

  5. Biermann CW, Semjonow A, Hertle L, Küchler T Entwicklung eines prostata-spezifischen Moduls zu Messung von Lebensqualität nach radikaler Prostatektomie. Forum DKG Suppl. 75 (1997)

  6. Fayers PM, Aaronson NK, Bjordal K, Curran D, and Groenvold M on behalf of the EORTC QUALITY OF LIFE STUDY GROUP. EORTC QLQ-C30 Scoring Manual: 2nd Edition” 1999, ISBN 2-930064-16-1, 78 pp

  7. Aaronson NK, Ahmedzai S, Bergman B, et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    Article  PubMed  CAS  Google Scholar 

  8. Staquet MJ, Fayers PM, Hays RD (eds) “Quality of life assessment in clinical trials: methods and practice” Oxford Medical Publications (1998)

  9. Riemer B “Lebensqualitätsmessung nach HDR-Brachytherapy und Teletherapie beim lokalisierten Prostatakarzinom” Univ. Diss., Kiel (1999)

  10. Carmines EG, Zeller RA Reliability and validity assessment, Sage Publ. (1979)

  11. Davis JW, Kuban DA, Lynch D, Schellhammer PF (2001) Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 166(3):947–952

    Article  PubMed  CAS  Google Scholar 

  12. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH (1998) The UCLA prostate cancer index: development, reliability, and validity of a health-related quality of life measure. Med Care 36:1002–1112

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by a grant from “Deutsche Krebshilfe e.V.”

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Volker Rohde.

Additional information

Supported by a grant from “Deutsche Krebshilfe e.V.”

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bestmann, B., Rohde, V., Siebmann, JU. et al. Validation of the German prostate-specific module. World J Urol 24, 94–100 (2006). https://doi.org/10.1007/s00345-005-0023-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-005-0023-5

Keywords

Navigation